Praxis Precision Medicines Sees 20% Surge on Positive Interim EMBOLD Trial Data
ByAinvest
Friday, Dec 5, 2025 6:46 am ET1min read
PRAX--
Praxis Precision Medicines' shares surged 20% in premarket trading after a Data Monitoring Committee recommended early stopping of the EMBOLD trial of Relutrigine based on interim efficacy results. The company plans to share topline results at the American Epilepsy Society Annual Meeting on December 6, 2025. The FDA meeting and NDA filing timing will be decided after the meeting. The stock closed yesterday at $189.97, up 2.05%, and is trading 23.18% higher at $234 in the pre-market.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet